Kernel

This article was originally published on Cannabis & Tech Today and appears here with permission. Cannabis legalization is opening the floodgates for alternative medicines. Ketamine in particular is showing promise and one company is taking a novel approach to researching the drug. Kernel,...

Cybin Inc. (NYSE:CYBN) and Kernel, two companies that undertook a joint feasibility study to evaluate the effects ketamine has on blood flow in the brain in late March, announced their results. In a video shared by Kernel, the company’s CEO and founder, Bryan...

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway,  announced Cybin Inc. (NYSE: CYBN), which is sponsoring the research that will make heavy use of Kernel Flow, a quantitative neuroimaging technology. Without...

Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. This “clinic model” will study and...